Crucially, these markets allow us to rigorously validate our technologys resilience in diverse and challenging weather conditions
Reliance on any information provided in this article is solely at your own risk
It also: Slows stomach emptying Improves insulin secretion Reduces blood sugar spikes When GLP-1 response weakens, appetite increases
Looking from 2023 to 2024, the latest year of data available, prescriptions and gross spending for Wegovy (first approved for obesity in 2021, approved for cardiovascular disease in 2024) and Mounjaro (approved for type 2 diabetes in 2022) more than doubled, and prescriptions and gross spending for Zepbound (first approved for obesity in 2023, approved for sleep apnea in 2024) increased more than fivefold
Petitions to either remove GLP-1 drugs from FDAs shortage list or place them on FDAs demonstrably difficult list will continue so all companies in the space should stay vigilant
The important signalling role of these hormones in the brain for obesity and type 2 obesity had been first flagged up following the discovery of leptin and later ghrelin
